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Background: Cribriform adenocarcinoma of salivary glands (CASG) is a rare, predominantly minor salivary gland 
tumor first described in 1999. Because the tumor shares morphologic and molecular features with polymorphous 
adenocarcinoma (PAC), in 2017, the World Health Organization (WHO) included CASG within the spectrum of 
PAC. Almost 75% of CASG harbor molecular alterations in the PRKD (Protein kinase D) gene family, and some 
cases show ARID1A (AT-rich interaction domain 1A)-PRKD1 or DDX3X (DEAD-Box Helicase 3 X-Linked)-PRKD1 
fusions. 
Case presentation: A 39-year-old man presented with headache and painless right cheek mass of two years 
duration. Imaging showed a well-circumscribed, lobulated 1.7-centimeter mass located in the superficial lobe of 
the right parotid gland. Fine needle aspiration (FNA) of the mass revealed a “salivary gland neoplasm of un-
certain malignant potential” (SUMP). Histopathology and immunohistochemical features of the resected tumor 
showed a primary salivary gland neoplasm with perineural invasion suggestive of cribriform adenocarcinoma of 
the salivary glands (CASG). Whole exome sequencing (WES) and transcriptome sequencing (RNAseq) of the 
tumor revealed a novel, intrachromosomal gene fusion: KTN1 (Kinectin1)-PRKD1. Sanger sequencing and 
Florescent insitu hybridization (FISH) break apart probe results subsequently confirmed the presence of the 
fusion. The patient recovered from surgery without complications. 
Conclusion: We report a novel fusion KTN1-PRKD1 in Cribriform Adenocarcinoma of the Salivary Glands located 
in the parotid gland. Importantly, this KTN1 fusion partner may account for other reports of intrachromosomal 
fusions in CASG in which the PRKD1 gene partner was not identified.   
1. Introduction: 
Cribriform adenocarcinoma of salivary glands (CASG) was first 
described in detail in 1999 as a distinctive salivary gland tumor limited 
to the tongue [1]. Subsequently, it was classified as a variant of poly-
morphous low-grade adenocarcinoma (PLGA) in 2005 by the WHO, as 
both entities share some histologic and molecular findings despite 
differing clinical profiles [2]. From 2005 until 2014, cribriform 
adenocarcinoma was reported at locations other than the tongue, and 
consequently the name was changed to cribriform adenocarcinoma of 
minor salivary glands (CAMSG) [3–5]. As familiarity with diagnostic 
criteria of CAMSG grew, rare cases were reported in the parotid gland. 
The name was then shortened to cribriform adenocarcinoma of the 
salivary glands (CASG). Although the clinical findings differ, the entity is 
still considered a type of polymorphous adenocarcinoma (low grade was 
dropped from its name) by the WHO. The 2017 edition of the WHO 
Abbreviations: CASG, Cribriform adenocarcinoma of salivary glands; WHO, World Health Organization; PRKD, protein kinase D; ARID1A, (AT-rich interaction 
domain 1A); DDX3X, DEAD-Box Helicase 3 X-Linked; KTN1, Kinectin1; PLGA, Polymorphous low-grade adenocarcinoma; PAC, Polymorphous adenocarcinoma; 
CAMSG, Cribriform adenocarcinoma of minor salivary glands; FNA, Fine needle aspiration; STUMP, Salivary gland neoplasm of uncertain malignant potential; AJCC, 
American Joint Committee on Cancer; WES, Whole exome sequencing; SCFD 1, Sec1 Family Domain Containing 1; NCBI, National Center for Biotechnology In-
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groups CASG with polymorphous adenocarcinoma (PAC) and is 
considered part of the spectrum of architectural patterns that can be 
seen [2]. This classification may change in the future after additional 
evidence into this emerging entity is obtained. 
CASG is histologically a low-grade malignant neoplasm exhibiting 
relatively indolent behavior. Incidence among primary salivary gland 
tumors is reported to be 0.5–1% [6]. Affected patients are adults with an 
approximately equal gender distribution. Patients typically present with 
cervical lymph node metastases. Despite this regional spread, CASG 
bears a favorable prognosis [7,8]. 
Molecular alterations of the PRKD gene family PRKD1, PRKD2, 
PRKD3 occur in both CASG and PAC. About 75% of PACs harbor an 
activating p.E710D point mutation in the PRKD1 gene, whereas 80% of 
CASG show gene fusions involving primarily PRKD1 but also PRKD2 and 
PRKD3 [8,9]. For CASG, ARID1A and DDX3X are common fusion part-
ners of PRKD1. However, the fusion-partner genes are not always 
identified or reported [3,8,9]. 
Herein we describe a case of a novel gene fusion, KTN1-PRKD1, 
occurring in a cribriform adenocarcinoma located in the parotid gland of 
a 39-year-old man. 
2. Case presentation 
2.1. Clinical summary 
A 39-year-old Caucasian man with a history of tobacco use and 
alcohol abuse presented to his family physician with a painless right 
cheek mass, diffuse headache, and ipsilateral hearing loss. He had 
noticed the mass two years previously and reported it was increasing in 
size. Imaging assessment by computed tomography (CT) of the head and 
neck revealed a well-circumscribed, lobulated 1.7-centimeter mass 
located in the superficial lobe of the right parotid gland (see Fig. 1). 
Adenopathy was absent, and additional imaging showed no evidence of 
metastatic disease. 
Fine needle aspiration (FNA) of the mass was successfully performed. 
Using the Milan cytology diagnostic classification system for salivary 
glands, the specimen was diagnosed as a “salivary gland neoplasm of 
uncertain malignant potential” (SUMP). 
2.2. Cytology findings 
The FNA specimen from the right parotid mass was hypercellular and 
consisted of tightly cohesive, branching groups of monomorphic tumor 
cells showing nuclear overlapping and a moderate N/C ratio. Globules of 
matrix material adhered to fenestrated tumor structures or floated freely 
in the background. The cell block contained cribriform fragments as well 
as fragments consistent with ‘glomeruloid’ structures. At high 
magnification, tumor nuclei resembled the nuclei of papillary thyroid 
carcinoma with fine, dusty chromatin, eccentric micronucleoli and 
scattered nuclear grooves (see Fig. 2). Immunohistochemical staining 
for c-kit (CD117) performed on the cell block showed nuclear and 
cytoplasmic reactivity in 80% of tumor cells. Cytologically, the differ-
ential diagnosis included adenoid cystic carcinoma, basal cell adenoma/ 
carcinoma and pleomorphic adenoma. Excision of the lesion was sug-
gested for definitive characterization. 
2.3. Histopathology and Immunohistochemistry 
Intraoperatively, the tumor formed a single firm, ill-defined mass 
that was fixed within the tail of the right parotid gland. Upon resection, 
the unencapsulated tumor measured 2.2 cm maximally, and cut sections 
revealed a firm, white uniform solid interior. At low magnification, the 
tumor exhibited a focally infiltrative border and a mixed cribriform 
(20%), glomeruloid (50%) and solid (20%) architecture disposed as 
irregular nodules embedded in a fibrous to hyalinized stroma. The 
cribriform nodules featured globules of pale, blue gray myxoid material. 
Rare small papillae (~3% of tumor) and tubules (~5–7% of tumor) were 
scattered among the solid cribriform and glomeruloid nodules. Tumor 
cells were monomorphic with clear to pale frothy eosinophilic cyto-
plasm and a medium N/C ratio. Tumor nuclei recapitulated resemblance 
to papillary thyroid carcinoma as noted previously on the cytology 
specimen with uniform features of overlapping nuclei with chromatin 
clearing, micronucleoli and nuclear grooving seen throughout the 
tumor. Mitotic figures were rare (<1/20 high magnification fields) and 
not atypical. Scattered psammoma bodies were also identified associ-
ated with tubules. Necrosis comprised less than 1% of tumor volume and 
was scattered as punctate foci. Perineural invasion was identified, but 
lymphovascular invasion was absent (see Fig. 3 for representative 
photomicrographs). Surgical margins were negative. The tumor was 
staged as pT2/pNX/pMX by the AJCC (American Joint Committee on 
Cancer) 8th Edition [10]. 
To further characterize the tumor, immunohistochemical (IHC) 
staining was performed on a Ventana Ultra automated platform (Roche 
Diagnostics, Indianapolis IN) with antigen retrieval using appropriate 
positive and negative controls and commercially available antibodies. 
Table 1 lists the resulting IHC profile (see Fig. 4 for representative IHC 
photomicrographs). The histologic features and IHC results suggested 
the tumor was primary to the salivary gland but not any of the entities 
suspected on the initial FNA biopsy exam. Therefore, additional mo-
lecular testing was performed. 
2.4. Molecular testing and Results: 
Whole exome sequencing (WES) and transcriptome sequencing 
(RNAseq) of a representative formalin-fixed paraffin embedded (FFPE) 
block of tumor (70% tumor cellularity with <1% necrosis) was carried 
out in a CLIA-certified laboratory (ASHION, Phoenix AZ). The custom 
xGEN target capture (Integrated DNA Technologies, Coralville IA) was 
used for WES. RNA libraries were prepared using KAPA HyperPrep with 
Riboerase (Kapa Biosystems, Wilmington, MA). Libraries were then 
sequenced using the Illumina HiSeq 2500 platform (Illumina, San Diego, 
CA). Sequence data were analyzed using GEM ExTra pipeline 4.0 
(ASHION), and the NCBI (National Center for Biotechnology Informa-
tion) GRCh37 (Genome Reference Consortium Human genome build 37) 
was the reference genome assembly used for alignment. Mean coverage 
for WES was approximately 440x. Approximately 120 million reads 
were obtained for RNAseq. Aggregated results showed that the tumor 
harbored a novel KTN1-PRKD1 fusion. In addition, eleven other variants 
of unknown significance were detected including nine missense vari-
ants, a splice donor variant and an SCFD1 (Sec1 Family Domain Con-
taining 1)-KTN1 fusion. 
Confirmatory Sanger Sequencing: Because of the diagnostic signifi-
cance of the KTN1-PRKD1 fusion, we performed Sanger sequencing to 
Fig. 1. CT scan shows a 1.7 cm mass in the superficial lobe of the right parotid 
gland (yellow circled region, coronal view). 
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Fig. 2. Cytologic features on fine needle aspiration biopsy: A) The tumor consisted of complex cohesive cellular fragments (DQ, 100X); B) Twisted fragment sug-
gesting a cribriform architecture with attached and free-floating pale metachromatic matrix globules (DQ, 400X); C) Nuclear features suggestive of PTC included 
chromatin clearing, eccentric micronucleoli and nuclear grooves (DQ, 600X); D) Tumor fragment with globular matrix and dense stromal fragment (Papanicolaou, 
400x); E) Glomeruloid structure on cell block (H&E, 600X); F) PTC-like nuclear features on the cell block (H&E, 600X). 
Fig. 3. Histologic features of excised tumor: A) The tumor comprised nodules of varying size embedded in a fibrotic to hyalinized stroma (H&E, 100X); B) Papillae 
were rare comprising ~3% of total tumor epithelial component (H&E, 200X); C) Glomeruloid nodule with rim of hyperchromatic cells and varying hyalinization 
(H&E, 400X); D) Cribriform nodule with myxoid pools (H&E, 400X); E) Psammoma bodies (H&E; 600X); F) Tumor cell nuclei with open chromatin mimicking 
papillary thyroid carcinoma (H&E, 600X). 
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alternately confirm the presence of the fusion in the tumor. RNA 
extracted from FFPE tumor sample was used as template for cDNA 
synthesis (Ampliseq™ cDNA Synthesis, Illumina, San Diego CA). The 
sequence of KTN1-PRKD1 fusion primers were forward primer: 5′- 
CAAGTTCGTGAGCAGATGGA-3′, reverse primer: 5′- 
CGAAGCTGGCTTTCTTGTTT-3′. Fusion PCR (Polymerase chain reac-
tion) was carried out using the following program: initial denature at 
94 ◦C for 5 min followed by 30 cycles of denature-annealing-extension at 
940 for 60 sec, 60 ◦C for 40 sec, 72 ◦C for 30 sec respectively and final 
extension at 72 ◦C for 5′. The PCR fragments were purified using Exo- 
SapIT™ (ThermoFisher Scientific, Waltham MA) and Sanger sequenced 
using BigDye™ terminator V3.1 (ThermoFisher Scientific). The PCR 
yielded a 392 bp product, and the fusion was confirmed by Sanger 
sequencing (see Fig. 5). 
For further confirmation of the genetic results, we performed Fluo-
rescent in situ hybridization (FISH) on formalin fixed, paraffin- 
embedded tissue using dual-color, break-apart probes. The FISH pre-
treatment protocol from Abbott Molecular (Abbott Molecular Inc) and 
hybridization protocol from Empire Genomics were followed. Probe 
location studies were validated by metaphase chromosomes. Standard 
FISH quality assurance and control procedures were used in the CLIA 
and CAP accredited Clinical Cytogenetics Laboratory at University of 
Kentucky. The FISH results showed separation of the KTN1 (5′, 3′) in 
45% of the tumor cells (see Fig. 6) and showed separation of the PRKD1 
(3′, 5′) in 47.5% of tumor cells (see Fig. 7), thus successfully confirmed 
the previous results. 
2.5. Clinical course 
The patient recovered from surgery without complications. Subse-
quently, he was lost to follow-up. 
3. Discussion and conclusion 
To our knowledge, this is the first reported case of cribriform 
adenocarcinoma of the salivary gland showing a KTN1-PRKD1fusion 
(about 75 cases of CASG have been reported in the literature) [8,11]. 
Given the relatively small number of published cases, it may be antici-
pated that additional novel findings, including molecular alterations, 
will be reported. 
In fact, investigators recently have further characterized molecular 
alterations in the CASG-PLGA spectrum of tumors substantiating an 
overlap in molecular pathogenesis comparable to the histologic overlap 
between the two carcinomas. The molecular alterations affect the same 
gene family, PRKD, but predominantly show point mutations in PAC and 
fusions in CASG [3,4,8,9,11,12]. In CASG, tumors display fusions 
involving PRKD1, PRKD2, PRKD3 (PRKD1/2/3). PRKD1 hotspot muta-
tions mainly occur in PAC, whereas fusions involving PRKD1, PRKD2, or 
Table 1 
Antibody reactivity in parotid tumor.  
Antibody Reactivity in Our Patient Clone Manufacturer 
Cytokeratin 7 Positive (90%) OV-TL 12/ 
30 
DAKO 
Cytokeratin 5/6 Positive (60%) D5/16 B4 DAKO 
p63 Positive (60%) D0-7 DAKO 
p40 Negative B628 BIOCARE 
Smooth Muscle 
Actin 
Positive (40%) 1 A4 DAKO 
S-100 protein Positive (100%; nuclear and 
cytoplasmic) 
Polyclonal DAKO 
CD117 (c-kit) Positive (80%) Polyclonal DAKO 
SOX-10 Positive (100%) EP 268 CELL 
MARQUE 
Mammaglobin Negative 304-1 A5 DAKO 
Beta-Catenin Normal (membranous) Beta- 
catenin-1 
DAKO 
DAKO (Agilent DAKO), Santa Clara CA; Biocare Medical, Pacheco CA; Cell 
Marque Corporation, Rocklin CA. 
Fig. 4. Immunohistochemical stains performed on excised tumor: A) Diffuse SOX10 nuclear expression (100X) B) Diffuse Keratin 7 expression of varying intensity 
(200X); C) Diffuse S-100 protein with variable nuclear and cytoplasmic expression; D) Patchy smooth muscle actin expression (600X); E) Patchy p63 expression 
(200X); F) No tumor expression of p40 with normal salivary gland expression at right (100X). 
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PRKD3 occur in CASG; however, these molecular events are not exclu-
sive, as 13% of histologically compatible CASG have point mutations, 
and 7% of histologically compatible PAC feature fusions [11]. Histo-
logically indeterminate cases (sharing mixed features of PAC and CASG) 
also variably show PRKD1 point mutations or PRKD1/3 fusions further 
supporting a shared pathogenesis between PAC and CASG [8,9,11]. 
The novel fusion discovered in our case is a KTN1-PRKD1. KTN1 is 
located on chromosome 14q22 and encodes an integral membrane 
protein of the Kinectin protein family. KTN1 functions as a receptor for 
the motor protein, kinesin and is involved in kinesin-driven vesicle 
motility. Kinectin also accumulates in integrin-based adhesion com-
plexes (IAC) [13,14]. In our patient’s tumor, the fusion occurs between 
exon 12 of PRKD1 and exon 9 of KTN1. As the previously reported 
ARID1A-PRKD1 and DDX3X-PRKD1 fusions lead to an over-expression of 
PRKD1 [9], the KTN1-PRKD1 fusion may also lead to PRKD1 over- 
expression. This is also supported by the gain-of-function point muta-
tion (p.E710D) in PRKD1 found in 75% of PACs. Intriguingly, two other 
PRKD1-rearranged tumors have been described that showed “evidence 
of intrachromosomal rearrangement” [9]. Possibly, those two cases may 
also contain KTN1-PRKD1 fusions. 
The protein kinase D gene (PRKD; 14q12) encodes the protein kinase 
D (PRKD) family of serine/threonine protein kinases. Three isoforms 
occur in humans: PKRD1, PRKD2 and PRKD3. PRKD1 alterations occur 
in colorectal, breast, esophageal, laryngeal, and numerous other cancers 
[9,15]. The isoforms variably interact with several signaling pathways 
including the MAPK8 (mitogen-activated protein kinase)/JNK1 (c-jun 
N-terminal kinase1), AKT (protein kinase B)/ERK (Extracellular Signal- 
Fig. 5. Electropherogram from Sanger sequencing showing fusion of KTN1 and PRKD1.  
Fig. 6. Fluorescence in situ hybridization (FISH) break-apart probe for KTN1 
gene showing the separation (sep) in the tumor nuclei. 
Fig. 7. Fluorescence in situ hybridization (FISH) break-apart probe for PRKD1 
gene showing the separation (sep) in the tumor nuclei. 
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Regulated Kinase), NF-kappaB and RAS regulated pathways [15]. Via 
these pathway interactions, PRKD isoforms play significant roles in 
fundamental cell activities including proliferation, apoptosis, epithelial 
to mesenchymal transition, angiogenesis, vesicle transport through the 
Golgi network, invasion, metastasis, and the innate immune response 
[15–17]. The effects of PRKD enzyme isoforms in tumors are complex, as 
they can promote or suppress tumors according to cancer type and 
isoform type. Within a single tumor type, such as breast ductal adeno-
carcinoma, one isoform exerts pro-tumoral effects, while another exerts 
anti-tumoral effects [15]. Even the same isoform may promote or sup-
press tumor growth in a single cancer type, based on results of various 
investigations [15]. Remarkably, despite the appositional complexity of 
PRKD isoform effects, in-vitro and in-vivo cancer models have demon-
strated that PRKD inhibitors show promise as an effective targeted 
therapy [15]. 
Importantly, given the novel KTN1 fusion partner, our case con-
formed to published histologic descriptions of CASG, and immunohis-
tochemical staining results also supported the diagnosis. Key diagnostic 
histologic findings present in our patient’s tumor that align with original 
diagnostic criteria by Michal et al (and confirmed in subsequent studies 
by Michal and others) include: 1) glomeruloid structures (nodules with 
irregular ‘filagree’ clefts and often a peripheral, palisading rim of 
smaller, hyperchromatic cells) and 2) nuclear features strongly remi-
niscent of the nuclear features of papillary thyroid carcinoma: ‘Orphan 
Annie’ change, chromatin clearing, eccentric micronucleoli and nuclear 
grooves [1,2,18]. Features consistent with classic polymorphous 
adenocarcinoma, including marked diversity of architectural patterns, 
targetoid whirling of single file tumor cells and slate blue stroma, were 
absent [7,18]. Psammoma bodies, found focally in our patient’s tumor, 
also uncommonly occur in CASG [18]. Tumors with at least 10% 
papillae and/or 30% cribriform pattern are associated with a worse 
disease-free survival [8,12]. At 3% papillae and 20% cribriform nodules, 
our patient’s tumor may have a lower risk for recurrence. 
As with the histologic features of our patient’s tumor, the immuno-
histochemical profile also conformed with published descriptions 
[3,18]. Our patient’s tumor expressed markers of basal/myoepithelial 
cells, CK5/6, S-100 protein, SMA, CK7 and SOX10, and showed the 
distinctive p63+/p40- pattern reported as a characteristic feature of 
PAC including CASG [19]. 
Publications detailing the cytologic features of CASG are few, con-
sisting of four, well-described cases [20,21,22]. Our patient’s cytology 
specimen contained cribriform structures, matrix globules and tumor 
cells with nuclear features suggestive of papillary thyroid carcinoma; 
these features were also uniformly reported in the three other cases. 
Additionally, our case and one of the three other cases contained glo-
meruloid structures [22]. Their presence in smears and minimally pro-
cessed cell blocks suggests glomeruloid structures are not artifacts of 
processing [1,18] but instead comprise a peculiar, innate growth pattern 
of CASG. 
Given the fact that there is morphologic overlap between PAC and 
CASG, this tumor would be best classified according to the WHO as 
polymorphous adenocarcinoma, cribriform variant, but we favor the 
terminology that is frequently seen throughout the literature of CASG 
due to the molecular findings and morphology. 
In summary, we describe a case of cribriform adenocarcinoma of the 
salivary glands that was located unusually in the parotid gland and 
showed a novel fusion gene, KTN1-PRKD1. The finding of a PRKD1 gene 
fusion in a parotid tumor with histologic and cytologic features of 
cribriform adenocarcinoma further supports the rare occurrence of this 
tumor in major salivary glands and continues to confirm the significant 
role of PRKD1 fusions in CASG. Possibly, given the report of other 
intrachromosomal PRKD1 gene rearrangements in CASG or CASG-like 
tumors, KTN1 may prove to be a recurrent fusion partner with PRKD1 
in cribriform adenocarcinoma of the salivary glands. 
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